Loading stock data…
NRXS
$6.80+0.13 (+1.95%)
After Hours$7.07+0.27 (+3.93%)· Last close Jun 9
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeurAxis, Inc. in the Healthcare sector is trading at $6.80 with a market capitalization of $88M. Wall Street consensus targets $11.00 (2 analysts), implying a +61.8% move over the next 12 months. The stock is currently 27% below its 52-week high of $9.33, remaining 42.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +61.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$6.80
Potential Downside
0%
Whystock Fair Value$6.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimula...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$87.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-126.72%
Volume
Today's trading volume
130,562
Recent News
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a sharp macro-driven sector rotation following geopolitical tensions, which triggered inflation fears and rising interest rate […]
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y
NRXS' first-quarter 2026 results show surging revenue and expanding gross margin as reimbursement improves under the Category I CPT code.
Neuraxis Inc (NRXS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Coverage Challenges
Neuraxis Inc (NRXS) reports significant revenue growth and strategic expansions, while navigating insurance coverage hurdles and financial adjustments.
The Zacks Analyst Blog Highlights Alphabet, Walmart, Micron Technology and NeurAxis
Alphabet, Walmart and Micron lead Zacks research as AI growth, retail strength and memory demand drive performance, while risks linger.
Top Stock Reports for Alphabet, Walmart & Micron
Alphabet rides AI-driven growth across Search, Cloud and subscriptions, but rising spending, debt and legal risks temper near-term flexibility.